Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[2.]
G. Sanna, M.L. Bertolaccini, A. Mathieu.
Central nervous system lupus: a clinical approach to therapy.
J Rheumatol, 30 (2003), pp. 985-992
[3.]
ACR ad Hoc Committee on Neuropsychiatric Lupus Nomenclature.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.
Arthritis Rheum, 42 (1999), pp. 599-608
[5.]
W.J. McCune, J. Golbus, W. Zeldes, P. Bohlke, R. Dunne, D.A. Fox.
Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus eryuthematosus.
N Engl J Med, 318 (1988), pp. 1423
[6.]
L.J. Jara, N.R. Capin, C. Lavalle.
Hyperviscosity syndrome as the initial manifestation of systemic lupus erythematosus.
J Rheumatol, 16 (1989), pp. 225
[7.]
G.L. Frichione, L.D. Kaufman, B.L. Gruber.
Electroconvulsive therapy and cyclophosphamide in combination for severe neuropsychiatric lupus with catatonia.
Am J Med, 88 (1990), pp. 442
[8.]
D.T. Boumpas, H. Yamada, N.J. Patronas, D. Scott, J.H. Klippel, J.E. Balow.
Pulse cyclophosphamide for severe neuropsychiatric lupus.
Q J Med, 81 (1991), pp. 875-984
[9.]
L. Barile, C. Lavalle.
Transverse myelitis in systemic lupus erythematosusthe effect of IV pulse methylprednisolone and cyclophosphamide.
J Rheumatol, 19 (1992), pp. 370-372
[10.]
J.M. Von Feldt, B.E. Ostrov, P.E. Callegari.
The use of cyclophosphamide in the tratment of CNS lupus [resumen].
Arthritis Rheum, 43 (1991), pp. S187
[11.]
K.F. Chan, M.L. Boey.
Transverse myelopathy in SLE: clinical features and functional outcomes.
Lupus, 5 (1996), pp. 294
[12.]
C.M. Neuwelt, S. Lacks, B.R. Kaye, J.B. Ellman, D.G. Borenstein.
Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus.
Am J Med, 98 (1995), pp. 32-41
[13.]
L. Barile, H. Juárez, R. Ariza, H. Fuentes, L.J. Jara.
Long-term outcome of transverse myeltis in systemic lupus erythematosus and primary antiphospholipid syndrome.
Artritis Rheum, 40 (1997), pp. S57
[14.]
V.F. Trevisani, A.A. Castro, J.F. Neves Neto, A.N. Attallah.
Cyclophosphamide vs. methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus.
Cochrane database Syst Rev, (2000),
[15.]
J.F. Téllez-Zenteno, J.M. Remes-Troche, R.O. Negrete-Pulido, L. Dávila-Maldonado.
Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging of six cases.
Lupus, 10 (2001), pp. 851-856
[16.]
C.C. MoK, C.S. Lau, E.Y. Chan, R.W.S. Wong.
Acute transverse myelopahty in systemic lupus erythematosus: clinical presentation, treatment and outcome.
J Rheumatol, 25 (1998), pp. 467-473
[17.]
L. Barile, R. Olguín, J.M. Miranda.
Long term outcome of neuropsychiatric lupus.
Lupus, 7 (1998), pp. S107
[18.]
P.C. Ramos, M.J. Méndez, P.R. Ames, M.A. Khamashta, G.R. Hughes.
Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus.
Clin Exp Rheumatol, 14 (1996), pp. 295-299
[19.]
H. Amano, S. Morimoto, H. Kaneko, Y. Tokano, Y. Takasaki, H. Hasimoto.
Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers.
Lupus, 9 (2000), pp. 478-480
[20.]
M.M. Ivanova, O.I. Bliziuk, I.V. Travikna.
The long term parenteral use of cyclophosphamide in treating patients with systemic lupus erythematosus and central nervous system involvement.
Ryumachi, 34 (1994), pp. 733-743
[21.]
L. Barile-Fabris, R. Ariza-Andraca, L. Olguín-Ortega, L.J. Jara, A. Fraga-Mouret, J.M. Miranda-Limón, et al.
Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.
Ann Rheum Dis, 64 (2005), pp. 620-625
[22.]
V. Strand.
New therapies for systemic lupus erythematosus.
Rheum Dis Clin North Am, 26 (2000), pp. 389-406
[23.]
K. Saito, M. Nawata, S. Nakayamada, M. Tokunaga, J. Tsukada, Y. Tanaka.
Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement.
Lupus, 12 (2003), pp. 798-800
[24.]
E. Tryseberg, I. Lindaren, A. Tarkowski.
Autologous stem cell trasplantation in a case of treatment resistant central nervous system lupus.
Ann Rhem Dis, 59 (2000), pp. 120-124
[25.]
J.O. Schroeder, H.H. Euler.
Treatment combining plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus.
Adv Exp Med Biol, 260 (1989), pp. 203-213
[26.]
M. Grisanti, A. Nader, R. Cacciuttolo.
Central nervous system involvement due to systemic lupus erythematosus/antiphospholipid syndrome: successful treatment with mycophenolate mofetil.
Lupus, 10 (2001), pp. S31
[27.]
Y. Sherer, Y. Levy, P. Langevitz, M. Lorber, F. Fabrizzi, Y. Shoenfeld.
Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin.
Clin Rheumatol, 18 (1999), pp. 170-173
[28.]
G. Valesini, R. Priori, A. Francia, G. Balestrieri, A. Tincani, P. Airo, et al.
Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate.
Springer Semin Immunopathol, 16 (1994), pp. 313-321
Copyright © 2005. Elsevier España S.L. Barcelona
